Active Ingredient History
Birabresib is an experimental small molecule inhibitor of BRD2, BRD3, and BRD4 under investigation for the treatment of cancer. It is in development by Merck & Co. It is currently in clinical trials for leukemia and glioblastoma. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Breast Neoplasms (Phase 1)
Carcinoma (Phase 1)
Carcinoma, Non-Small-Cell Lung (Phase 1)
Glioblastoma (Phase 1/Phase 2)
Leukemia, Myeloid, Acute (Phase 1/Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 1)
Lymphoma, Large-Cell, Immunoblastic (Phase 1)
Multiple Myeloma (Phase 1)
Pancreatic Neoplasms (Phase 1)
Triple Negative Breast Neoplasms (Phase 1)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue